Antonio Passaro: Exploring Antibody-Drug Conjugates in lung cancer
Antonio Passaro, Lung Cancer Oncologist & Researcher at Instituto Europeo di Oncologia, posted the following on LinkedIn:
“Jan 18, 2025: It was a true honor to participate at the iMAX Oncology Summit held in the vibrant city of Beijing. This incredible event brought together hundreds of colleagues and experts from across the country, all united by the mission to advance oncology care.
During my presentation, I had the privilege of exploring one of the most promising and cutting-edge topics in oncology: the development of Antibody-Drug Conjugates (ADCs) in the treatment of patients affected by lung cancer, with or without driver gene alterations. I shared my insights on the strengths, challenges, and unresolved issues, while emphasizing the immense potential of these therapies. However, much work still lies ahead to ensure these innovative treatments become widely accessible to patients in need.
With 2025 set to be a year of significant advancements in the field, there’s no doubt that exciting developments lie ahead—stay tuned! A heartfelt thank you to Lei Cheng Lin and Veronica Chen for their unwavering support throughout this journey. I would also like to extend my gratitude to the entire MSD China Oncology team for the great success of the event and for the invitation!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023